Foundation Medicine ( Foundation Medicine)

Primary tabs

Foundation Medicine's picture

Management

Contact Address

About Foundation Medicine

Foundation Medicine (NASDAQ:FMI) is a molecular information company dedicated to a transformation in cancer care in which treatment is informed by a deep understanding of the genomic changes that contribute to each patient's unique cancer.

Foundation Medicine press release, blog etc

Fri, 12/05/2025 - 01:15 Foundation Medicine Achieves Historic Milestone of 100 Approved and Active Companion Diagnostic Indications, Solidifying Leadership in Precision Medicine
Thu, 10/30/2025 - 12:56 Foundation Medicine and Manifold Partner to Accelerate Drug Discovery and Development by Bringing AI-Enabled Analytics to FoundationInsights
Mon, 10/13/2025 - 20:16 Foundation Medicine Spotlights Scientific Achievements Across its Portfolio of High-Quality Biomarker Tests at the 2025 European Society for Medical Oncology (ESMO) Congress
Tue, 09/23/2025 - 12:19 Foundation Medicine Launches Molecular Residual Disease (MRD) Test for Research Use in Early to Late-Stage Cancers Through its FlexOMx Lab
Fri, 05/23/2025 - 19:24 Foundation Medicine Expands Immunohistochemistry (IHC) Testing Portfolio to Include MET IHC Testing
Thu, 05/22/2025 - 19:15 Foundation Medicine to Present Over 15 Abstracts at the 2025 ASCO Annual Meeting
Tue, 02/18/2025 - 18:53 Foundation Medicine Collaborates with Sumitomo Pharma America to Advance Investigational Treatment for Patients with Acute Leukemia with NPM1 Mutations or KMT2A Rearrangements Using the FoundationOneHeme Platform
Tue, 02/04/2025 - 18:45 Foundation Medicine to Launch Hereditary Germline Tests, FoundationOneGermline and FoundationOneGermline More, in the United States Through a Partnership with Fulgent Genetics
Fri, 01/17/2025 - 19:17 U.S. Food and Drug Administration Approves FoundationOneCDx as a Companion Diagnostic for OJEMDA (tovorafenib) to Treat the Most Common Form of Childhood Brain Tumor in Pediatric Patients
Wed, 05/29/2024 - 16:28 Foundation Medicine and PMV Pharma Announce Collaboration to Develop Companion Diagnostic for Rezatapopt, a First-In-Class, Investigational, Selective p53 Y220C Reactivator
Sat, 05/25/2024 - 11:00 Foundation Medicine Announces Details of Over 20 Presentations at the 2024 ASCO Annual Meeting
Thu, 05/23/2024 - 00:47 Foundation Medicine Launches RNA Sequencing Test, FoundationOneRNA, in the U.S.
Tue, 12/20/2022 - 19:02 Foundation Medicine Receives FDA Approval for FoundationOneLiquid CDx as a Companion Diagnostic for a Certain Group of Tyrosine Kinase Inhibitors for Treatment of Non-Small Cell Lung Cancer Patients
Mon, 11/14/2022 - 16:27 Foundation Medicine Launches FoundationReport+, a New Digital Reporting Experience to Streamline Precision Cancer Care
Tue, 09/20/2022 - 21:48 Foundation Medicine and Day One Biopharmaceuticals Announce Global Collaboration to Advance Pediatric Cancer Care
Mon, 09/12/2022 - 23:56 Foundation Medicine to Share 14 Abstracts at the 2022 European Society for Medical Oncology (ESMO) Congress Demonstrating the Power of Genomic Profiling to Advance Cancer Care
Sun, 09/11/2022 - 21:31 Foundation Medicine and Relay Therapeutics Collaborate to Develop FoundationOneCDx as a Companion Diagnostic for Relays Investigational FGFR2 Inhibitor, RLY-4008
Wed, 06/08/2022 - 19:37 U.S. FDA Approves FoundationOneCDx as a Companion Diagnostic for Rozlytrek (entrectinib)
more

InfoBox

HomePagewww.foundationmedicine.com
Twittertwitter.com/foundationatcg
YouTubeyoutube.com/FoundationMedicine
LinkedInlinkedin.com/company/foundation-medicine
Wikipediaen.wikipedia.org/wiki/Foundation_Medicine